1. Market Research
  2. > Pathology
52 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Market Spotlight: Mantle Cell Lymphoma

  • $ 1318
  • November 2019
  • 47 pages

Key Takeaways The analyst estimates that in 2017, there were approximately ##, ## incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to ##, ## incident cases by 2026.

  • Drug Development
  • Lymphoma
  • World

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • $ 22000
  • January 2019
  • 510 pages

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026 CONTENTS ## FORECAST: FOLLICULAR LYMPHOMA (Published on ## January 2019) ## OVERVIEW ## RECENT FORECAST UPDATES ## MARKET DYNAMICS ## FORECAST AND FUTURE TRENDS ## MARKET DEFINITION AND METHODOLOGY ## PRIMARY

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

  • $ 22000
  • October 2018
  • 475 pages

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence Table of Contents (Forecast, Treatment, Epidemiology Datapacks included) ## FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA (Published on ## October 2018) ## OVERVIEW ## RECENT FORECAST UPDATES

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Market Spotlight: Gastrointestinal Stromal Tumor (GIST), Pharma Intelligence

  • $ 1318
  • April 2020
  • 43 pages

lymphoma, and proportion of individuals with TLS, 2017 ## Table ##: Incident cases of TLS in Burkitt’s lymphoma, 2017–## ## Table ##: Marketed drugs for TLS ## Table ##: Parent patents in TLS ## Table ##: Historical global sales, by drug ($m), 2014–## ## Table ##: Forecasted global sa

  • Clinical Trial
  • Drug Development
  • Lymphoma
  • China
  • World

Betalutin

  • $ 10000
  • January 2019
  • 17 pages

CD## is highly expressed in B cells and B-cell lymphomas.

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Aliqopa

  • $ 10000
  • January 2019
  • 18 pages

Aliqopa CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Aliqopa : NHL: Follicular lymphoma (FL) LIST OF FIGURES ## Figure ##: Aliqopa for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Aliqopa for follicular

  • Cancer
  • Lymphoma
  • Pathology
  • Targeted Therapy
  • Therapy

INCB050465

  • $ 10000
  • January 2019
  • 16 pages

INCB## CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## INCB## : NHL: Follicular lymphoma (FL) LIST OF FIGURES ## Figure ##: INCB## for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of INCB## for folli

  • Cancer
  • Lymphoma
  • Pathology
  • United States
  • Forecast

umbralisib

  • $ 10000
  • January 2019
  • 26 pages

umbralisib CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## umbralisib : NHL: Follicular lymphoma (FL) ## umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Umbralisib for follicular lymphoma – SWOT analysis ## Figure ##: Datamo

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

lisocabtagene maraleucel

  • $ 10000
  • January 2019
  • 30 pages

lisocabtagene maraleucel CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## lisocabtagene maraleucel : NHL: Follicular lymphoma (FL) ## lisocabtagene maraleucel : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Lisocabtagene maraleucel for follicula

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Pathology

Yescarta

  • $ 10000
  • January 2019
  • 19 pages

Yescarta CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Yescarta : NHL: Follicular lymphoma (FL) ## Yescarta : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Yescarta for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor H

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Pathology

Revlimid

  • $ 10000
  • January 2019
  • 56 pages

Revlimid CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Revlimid : NHL: Follicular lymphoma (FL) ## Revlimid : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Revlimid : Multiple myeloma ## Revlimid : NHL: Mantle cell lymphoma (MCL) LIST OF FIGURES ## Figur

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • Japan

Kinenza

  • $ 10000
  • October 2018
  • 17 pages

Kinenza CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Kinenza : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Kinenza for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Kinen

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • United States

MOR208

  • $ 10000
  • October 2018
  • 17 pages

MOR## CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## MOR## : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: MOR## for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for MOR## i

  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • United States

polatuzumab vedotin

  • $ 10000
  • October 2018
  • 18 pages

polatuzumab vedotin CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## polatuzumab vedotin : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Polatuzumab vedotin for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy

Selinexor

  • $ 10000
  • October 2018
  • 32 pages

Selinexor CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## selinexor : NHL: Diffuse large B-cell lymphoma (DLBCL) ## selinexor : Multiple myeloma LIST OF FIGURES ## Figure ##: Selinexor for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcar

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

Blincyto

  • $ 10000
  • October 2018
  • 25 pages

Blincyto CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Blincyto : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Blincyto : Acute lymphoblastic leukemia (ALL) LIST OF FIGURES ## Figure ##: Blincyto for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamon

  • Biopharmaceutical
  • Cancer
  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology

Bavencio

  • $ 10000
  • October 2018
  • 82 pages

Bavencio CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Bavencio : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Bavencio : Non-small cell lung cancer (NSCLC) ## Bavencio : Gastric cancer ## Bavencio : Head and neck cancer ## Bavencio : Ovarian cancer ## Bavencio : Bladde

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • Japan

Gazyva

  • $ 10000
  • January 2019
  • 40 pages

Gazyva CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Gazyva : Chronic lymphocytic leukemia (CLL) ## Gazyva : NHL: Follicular lymphoma (FL) ## Gazyva : NHL: Mantle cell lymphoma (MCL) LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of

  • Biopharmaceutical
  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy

Imbruvica

  • $ 10000
  • January 2019
  • 51 pages

Imbruvica CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Imbruvica : Chronic lymphocytic leukemia (CLL) ## Imbruvica : NHL: Follicular lymphoma (FL) ## Imbruvica : NHL: Diffuse large B-cell lymphoma (DLBCL) ## Imbruvica : NHL: Mantle cell lymphoma (MCL) L

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • European Union

Kymriah

  • $ 10000
  • January 2019
  • 38 pages

Kymriah CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Kymriah : Chronic lymphocytic leukemia (CLL) ## Kymriah : NHL: Follicular lymphoma (FL) ## Kymriah : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessm

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • Pathology
  • European Union
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on